Kliniske studier med pågående inklusjon
- Et komparativt studium av tumorceller i lymfeknuter, perifert blod, benmarg og primærtumor hos pasienter med brystkreft (Oslo2).
Prosjektleder: OSBREAC/Kristine Kleivi - Improved breast cancer therapy (I-BCT-1) in the neoadjuvant and metastatic setting: A phase 2 clinical trial protocol studying biological rationale for the optimal selection of treatment regimens
Prosjektleder: Olav Engebråten - Den prospektive studie (av seneffekter etter behandling av brystkreft og lymfekreft)
Prosjektleder: Cecilie Kiserud - A study evaluating the pregnancy outcomes and safety of interrupting endocrine therapy for young women with endocrine responsive cancer who desire pregnancy
Prosjektleder: Anna Sætersdal - A randomized placebo-controlled phase II study evaluating atezolizumab combined with immunogenic chemotherapy in patients with metastatic triple-negative breast cancer (ALICE)
Prosjektleder: Jon Amund Kyte - A randomized phase IIb study evaluating immunogenic chemotherapy combined with ipilimumab and nivolumab in patients with luminal B breast cancer (ICON)
Prosjektleder: Jon Amund Kyte - Establishment of Molecular profiling for Individual clinical routine Treatment decision in Early Breast Cancer (EMIT1)
Prosjektleder: Bjørn Naume - Optimal Personalised Treatment of early breast cancer using Multi-parameter Analysis (OPTIMA/EMIT2)
Prosjektleder: Bjørn Naume
Øvrige studier og prosjekter
- Neoadjuvant Avastin in Breast Cancer (Neo-Ava) A randomized phase 2 trial (NeoAva ML 21744).
Prosjektleder: Olav Engebråten - ALTTO Adjuvant Lapatinib and/or Trastuzumab Treatment Optimisation study. A randomised, multi-centre, open-label, phase III study of adjuvant lapatinib, trastuzumab, their sequence and their combination in patients with HER2/ErbB2 positive primary breast cancer.
Prosjektleder: Anna Sætersdal - NeoALTTO (Neoadjuvant Lapatinib and/or Trastuzumab Treatment Optimisation) study. A randomised, multicentre, open-label, phase III study of neoadjuvant lapatinib, trastuzumab, and their combination plus paclitaxel in women with HER2/ErbB2 positive primary breast cancer.
Prosjektleder: Bjørn Naume - Secondary Adjuvant (rescue) Treatment with docetaxel (Taxotere) and detection of isolated tumor cells in bone marrow as a surrogate marker for effect - in node positive and high risk node negative breast cancer after standard adjuvant epirubicin-containing treatment (SATT)
Prosjektleder Bjørn Naume - Energy Balance and Breast Cancer Aspects (EBBA2).
Prosjektleder: Inger Thune - Targeting occult tumor cells in early breast cancer (inkl Oslo1).
Prosjektleder: Bjørn Naume - Effekt av gruppeintervensjon på angst, depresjon og livskvalitet hos brystkreft opererte kvinner. En randomisert, kontrollert, prospektiv studie. Studien er i samarbeid med Sykehuset i Vestfold. Studien er registert i Cinical Trial.gov nr NCT00289432.
Prosjektleder: Inger Schou Bredal - The Healing Breath program as an adjuvant therapy for cancer – a randomized, kontrollert, prospektiv studiestudy.
Prosjektleder Fahri Saatcioglu - Kronisk smerte som følge av brystkreftbehandling. En kartlegging av prevalensen av kronisk smerte som følge av brystkreftbehandling, samt å kartlegge smerte-karakteristikk, lokalisasjon, intensitet, og kvalitet av smerten.
Prosjektleder Inger Schou Bredal - A multicenter, single arm study of trastuzumab emtansine (T-DM1) in HER2 positive locally advanced or metastatic breast cancer patients who have received prior anti-HER2 and chemotherapy based treatment (KAMILLA MO28231).
Prosjektleder: Kristin Reinertsen - The efficacy of T-DM1 compared with treatment of physician’s choice in patients with HER2-positive metastatic breast cancer who have received at least two prior regimens of HER2 directed therapy (TH3RESA).
Prosjektleder: Bjørn Naume - A randomized double-blind, placebo-controlled study of LEE011 in combination with letrozole for the treatment of postmenopausal women with hormone receptor positive, HER2 negative, advanced breast cancer who received no prior therapy for advanced disease (MONALEESA-2)
Prosjektleder: Erik Wist - A study of Kadcyla (Trastuzumab Emtansine) plus Perjeta (Pertuzumab) following Anthracyclines in comparison with Herceptin (Trastuzumab) plus Perjeta and a Taxane following Anthracyclines as adjuvant therapy in patients with operable HER2-positive primary breast cancer (KAITLIN)
Prosjektleder: Olav Engebråten - A multicenter, multinational, phase II study to evaluate pertuzumab in combination with trastuzumab and standard neoadjuvant antracycline – based chemotherapy in patients with HER2-positive, locally advanced, inflammatory, or early stage breastcancer (Berenice)
Prosjektleder: Hege Oma Ohnstad - Establishment of Molecular profiling for Individual Treatment decisions in Early Breast Cancer (EMITEBC) Treatment decisions beyond routine histopathology and immunopathology for improved classification and treatment stratification in early breast cancer; establishment, testing and implementation of molecular profiling-based diagnostics.
Prosjektleder: Bjørn Naume - A randomized double-blind, placebo-controlled study of ribociclib in combination with fulvestrant for the treatment of postmenopausal women with hormone receptor positive, HER2-negative, advanced breast cancer who have received no or only one line of prior endocrine treatment (MONALEESA-3)
Prosjektleder: Anna Barbro Sætersdal - A phase II randomized, double-blind, placebo-controlled trial of radium-223 dichloride vs. placebo when administered to Her 2 neg hormone receptor positive breast cancer with bone metastases treated with standard of care hormonal treatment
Prosjektleder: Bjørn Naume - Double blind, placebo controlled study of BKM120 with fulvestrant, in postmenopausal women with hormone receptor positive, HER2 negative AI treated, locally advanced or metastatic breast cancer who progressed on or after mTOR inhibitor based treatment (Belle3).
Prosjektleder: Olav Engebråten -
A phase II randomized, double-blind, placebo-controlled trial of radium-223 dichloride vs. placebo when administered to Her 2 neg hormone receptor positive breast cancer with bone metastases treated with exemestane and everolimus as background therapy
-
Prosjektleder: Bjørn Naume